
Annual report 2022
added 12-21-2024
Genetron Holdings Limited EBITDA 2011-2026 | GTH
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Genetron Holdings Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -518 M | -268 M | -307 M | -233 M | -134 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -134 M | -518 M | -292 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Diagnostics research industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
1.67 B | $ 119.04 | 0.74 % | $ 36.2 B | ||
|
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.83 | -4.39 % | $ 91.8 K | ||
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M | ||
|
Aspira Women's Health
AWH
|
-32.5 M | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
-749 M | $ 23.54 | -6.44 % | $ 247 M | ||
|
Celcuity
CELC
|
-113 M | $ 107.4 | -0.83 % | $ 4.24 B | ||
|
Akumin
AKU
|
70.1 M | - | -17.87 % | $ 25.9 M | ||
|
Castle Biosciences
CSTL
|
24.7 M | $ 27.57 | -1.5 % | $ 766 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-3.26 M | - | - | $ 562 M | ||
|
Heska Corporation
HSKA
|
-6.33 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-20.2 M | - | -20.0 % | $ 1.06 M | ||
|
Charles River Laboratories International
CRL
|
428 M | $ 175.69 | -1.63 % | $ 8.71 B | ||
|
Fulgent Genetics
FLGT
|
-49 M | $ 13.79 | -2.89 % | $ 417 M | ||
|
Accelerate Diagnostics
AXDX
|
-12.3 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
652 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-35.1 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-6 M | - | - | $ 7.1 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
416 M | - | - | $ 10.7 B | ||
|
Motus GI Holdings
MOTS
|
-11.5 M | - | -34.28 % | $ 263 K | ||
|
Biodesix
BDSX
|
-28.7 M | $ 15.5 | -1.59 % | $ 2.01 B | ||
|
Biocept
BIOC
|
-30.3 M | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
47.2 M | - | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
-90 M | $ 1.12 | -1.75 % | $ 1.42 M | ||
|
Quest Diagnostics Incorporated
DGX
|
2.13 B | $ 208.36 | -0.91 % | $ 23.1 B | ||
|
Danaher Corporation
DHR
|
5.44 B | $ 204.01 | -0.91 % | $ 145 B | ||
|
Organovo Holdings
ONVO
|
-12.4 M | - | -2.3 % | $ 19.4 M | ||
|
Exact Sciences Corporation
EXAS
|
-81.4 M | $ 103.37 | 0.02 % | $ 19.5 B | ||
|
Bioventus
BVS
|
-24.4 M | $ 8.74 | -0.34 % | $ 548 M | ||
|
DarioHealth Corp.
DRIO
|
-55.7 M | $ 10.3 | -4.19 % | $ 292 M | ||
|
DexCom
DXCM
|
1.16 B | $ 73.08 | -0.95 % | $ 28.5 B | ||
|
PerkinElmer
PKI
|
762 M | - | -0.91 % | $ 14.7 B | ||
|
Psychemedics Corporation
PMD
|
-1.22 M | - | -1.84 % | $ 15.3 M | ||
|
QIAGEN N.V.
QGEN
|
301 M | - | - | $ 10.6 B | ||
|
Quotient Limited
QTNT
|
-73.9 M | - | -11.32 % | $ 1.1 M | ||
|
ICON Public Limited Company
ICLR
|
1.59 B | $ 108.7 | 0.4 % | $ 8.97 B | ||
|
IDEXX Laboratories
IDXX
|
1.51 B | $ 635.54 | -0.18 % | $ 51.1 B | ||
|
Illumina
ILMN
|
-479 M | $ 129.56 | -2.51 % | $ 20.6 B | ||
|
Renalytix AI plc
RNLX
|
-29.2 M | - | 5.66 % | $ 22.7 M | ||
|
VolitionRx Limited
VNRX
|
-25.9 M | $ 0.2 | -1.28 % | $ 19.2 M | ||
|
CareDx, Inc
CDNA
|
-15.8 M | $ 18.8 | 0.29 % | $ 1 B | ||
|
Chembio Diagnostics
CEMI
|
-21.1 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-25.8 M | - | - | $ 9.42 M | ||
|
Guardant Health
GH
|
-398 M | $ 93.3 | 1.16 % | $ 11.7 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.07 B | $ 282.99 | -1.21 % | $ 23.5 B | ||
|
Lantheus Holdings
LNTH
|
381 M | $ 78.84 | 3.33 % | $ 5.32 B | ||
|
IQVIA Holdings
IQV
|
3.33 B | $ 173.96 | -0.18 % | $ 29.9 B | ||
|
Brainsway Ltd.
BWAY
|
-5 M | $ 11.59 | -51.08 % | $ 99.4 M | ||
|
Co-Diagnostics
CODX
|
-41.5 M | - | - | $ 79.8 M | ||
|
Soleno Therapeutics
SLNO
|
11.4 M | $ 37.72 | -3.43 % | $ 1.92 B |